# AO GENERIUM clinical trials: 31 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 31 trials with AO GENERIUM as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by AO GENERIUM: 31 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/ao-generium

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 31
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 25 newest of 31, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 28, 2026 | NCT07844148 | A Study to Compare GNR-139 and Eylea® in Patients With nAMD | AO GENERIUM | Phase 3 | Recruiting | nAMD | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07844148) |
| June 29, 2026 | NCT07673809 | A Study to Evaluate the Tolerability, Safety and Efficacy of GNR-097 Gene Therapy in Pediatric Patients With Duchenne Muscular Dystrophy | AO GENERIUM | Phase 1/2 | Recruiting | Duchenne Muscular Dystrophy | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07673809) |
| September 4, 2025 | NCT07155499 | A Clinical Trial for Evaluation of Efficacy, Safety and Immunogenicity of GNR-127 (Recombinant ABP Antigen Protein Which Carries a Birch... | AO GENERIUM | Phase 1/2 | Completed | Rhinitis, Allergic, Seasonal | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07155499) |
| August 28, 2025 | NCT07146360 | Efficacy and Safety Study of Proposed Biosimilar Product Reveliza vs Actilise in Patients With ST-segment Elevation Myocardial Infarction | AO GENERIUM | Phase 3 | Completed | Myocardial Infarction (MI) | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07146360) |
| July 11, 2024 | NCT06497491 | An Efficacy and Safety Study of GNR-086 (Canakinumab Biosimilar) and Ilaris® in Patients With Adult-onset Still&#39;s Disease | AO GENERIUM | Phase 3 | Completed | Still's Disease Adult Onset | 118 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06497491) |
| July 10, 2024 | NCT06494345 | A Study of Genolair in Two Dosage Forms (Solution and Lyophilisate) and Xolair® in Healthy Volunteers | AO GENERIUM | Phase 1 | Completed | Allergic Asthma | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06494345) |
| July 5, 2024 | NCT06488664 | An Efficacy and Safety Study of GNR-068 (Ustekinumab Biosimilar) and Stelara® in the Treatment of Patients With Moderate to Severe Plaque... | AO GENERIUM | Phase 3 | Completed | Plaque Psoriasis | 422 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06488664) |
| July 5, 2024 | NCT06488521 | A Safety and Pharmacokinetics Study of Complarate (Tocilizumab Biosimilar Solution) and Actemra® in Healthy Volunteers | AO GENERIUM | Phase 1 | Completed | Healthy Volunteers | 256 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06488521) |
| July 1, 2024 | NCT06481215 | A Safety and Pharmacokinetics Study of Ustekinumab Biosimilar GNR-068 and Stelara® in Healthy Volunteers | AO GENERIUM | Phase 1 | Completed | Healthy Volunteers | 122 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06481215) |
| July 1, 2024 | NCT06481202 | A Safety and Pharmacokinetic Study of Complarate (Tocilizumab Biosimilar) and Actemra® in Healthy Volunteers | AO GENERIUM | Phase 1 | Completed | Healthy Volunteers | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06481202) |
| July 1, 2024 | NCT06481189 | A Safety, Pharmacokinetics and Pharmacodynamics Study of GNR-086 and Ilaris® in Healthy Volunteers | AO GENERIUM | Phase 1 | Completed | Healthy Volunteers | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06481189) |
| June 26, 2024 | NCT06475508 | Comparison of Complarate® (Tocilizumab Biosimilar) and Actemra® in Patients With Rheumatoid Arthritis | AO GENERIUM | Phase 3 | Completed | Rheumatoid Arthritis | 465 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06475508) |
| June 26, 2024 | NCT06475404 | A Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers | AO GENERIUM | Phase 1 | Completed | Mucopolysaccharidosis Type II, Metabolic Diseases | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06475404) |
| November 1, 2022 | NCT05601999 | Study of Efficacy and Safety of GNR-060 vs Metalyse in Patients With ST Elevation Myocardial Infarction | AO GENERIUM | Phase 3 | Completed | ST Elevation Myocardial Infarction | 244 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05601999) |
| August 8, 2022 | NCT05492409 | Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients | AO GENERIUM | Phase 3 | Completed | Idiopathic Thrombocytopenic Purpura | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05492409) |
| February 2, 2022 | NCT05220878 | Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP | AO GENERIUM | Phase 3 | Completed | Idiopathic Thrombocytopenic Purpura | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05220878) |
| January 26, 2022 | NCT05208281 | A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II | AO GENERIUM | Phase 2/3 | Active not recruiting | Mucopolysaccharidosis Type II, Metabolic Diseases | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05208281) |
| May 24, 2021 | NCT04898309 | Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema | AO GENERIUM | Phase 2/3 | Withdrawn | Hereditary Angioedema | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04898309) |
| February 11, 2021 | NCT04749810 | Observational Study of Elizaria® in aHUS Patients | AO GENERIUM | Observational | Completed | Atypical Hemolytic Uremic Syndrome, aHUS | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04749810) |
| December 22, 2020 | NCT04679103 | A Safety and Immunogenicity Study in Long-term Treatment of Eculizumab (JSC "GENERIUM", Russian Federation) | AO GENERIUM | Phase 3 | Completed | Paroxysmal Nocturnal Hemoglobinuria | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04679103) |
| December 17, 2020 | NCT04671810 | Prospective Observational Study of Long-term Pathogenic Treatment of Elizaria® | AO GENERIUM | Observational | Completed | Paroxysmal Nocturnal Hemoglobinuria | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04671810) |
| December 14, 2020 | NCT04667039 | Efficacy, Safety, pharmacokinetiсs, Immunogenicity of GNR-067 and Lucentis® | AO GENERIUM | Phase 3 | Unknown | Age Related Macular Degeneration (ARMD) | 408 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04667039) |
| October 29, 2020 | NCT04607629 | An Efficacy and Safety Study of Genolar® and Xolar® in the Persistent Atopic Bronchial Asthma | AO GENERIUM | Phase 3 | Completed | Bronchial Asthma | 192 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04607629) |
| October 26, 2020 | NCT04601584 | GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL | AO GENERIUM | Phase 1/2 | Terminated | B-precursor Acute Lymphoblastic Leukemia, ALL, GNR-084 | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04601584) |
| October 23, 2020 | NCT04601389 | Study of Pharmacokinetics, Pharmacodynamics and Safety Assessment of GNR-044 (JSC GENERIUM, Russia) and Xolair® | AO GENERIUM | Phase 1 | Completed | Healthy Volunteers | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04601389) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 10 |
| Phase 1/2 | 3 |
| Phase 2/3 | 2 |
| Phase 3 | 14 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 25 |
| Recruiting | 2 |
| Active not recruiting | 1 |
| Unknown | 1 |
| Terminated | 1 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Immune System Diseases | 7 |
| Genetic Diseases, Inborn | 6 |
| Hypersensitivity | 5 |
| Respiratory Tract Diseases | 4 |
| Thrombocytopenia | 3 |
| Hemorrhage | 3 |
| Urticaria | 3 |
| Mucopolysaccharidosis II | 3 |
| Metabolic Diseases | 3 |
| Lysosomal Storage Diseases | 3 |
| Neurobehavioral Manifestations | 3 |
| Neurologic Manifestations | 3 |
| Genetic Diseases, X-Linked | 3 |
| Hemoglobinuria, Paroxysmal | 3 |
| Hematologic Diseases | 3 |
| Pathologic Processes | 3 |
| Purpura, Thrombocytopenic, Idiopathic | 2 |
| Purpura | 2 |
| Ecchymosis | 2 |
| Angioedemas, Hereditary | 2 |
| Angioedema | 2 |
| Myocardial Infarction | 2 |
| Mucopolysaccharidoses | 2 |
| Asthma | 2 |
| Hemolysis | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Import and export companies in the United States](https://specstream.ai/data/businesses/import-and-export-companies/united-states)
- [Peruvian restaurants in the United States](https://specstream.ai/data/businesses/peruvian-restaurants/united-states)
- [Trailer repair shops in the United States](https://specstream.ai/data/businesses/trailer-repair-shops/united-states)
- [Belgian restaurants in the United States](https://specstream.ai/data/businesses/belgian-restaurants/united-states)
- [Environmental testing companies in the United States](https://specstream.ai/data/businesses/environmental-testing-companies/united-states)
- [Leather products manufacturers in the United States](https://specstream.ai/data/businesses/leather-products-manufacturers/united-states)
